Physicians' Academy for Cardiovascular Education

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

Sep. 20, 2017

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

Aug. 27, 2017

HIV as a model to study effect of chronic inflammation on CV risk

Mar. 16, 2017 - VBWG ACC 2017

Lowering inflammation to address residual CV risk

Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

Inflammation, the immune system and atherosclerosis

July 7, 2015 - Amsterdam IAS

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD

Statin-loaded HDL nanoparticles

Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation: targets for intervention

Oct. 3, 2013 - Snapshot 2013 - Ulf Landmesser

Inflammation & cardiovascular disease: Exploring new options for intervention

Sep. 30, 2013

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

Inflammation expert opinions

Aug. 28, 2017 - ESC 2017, Barcelona, Spain
Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.

Inflammation Expert Opinions Philippe Gabriel Steg reflects on the CANTOS trial results that confirm the long-standing hypothesis that inflammation plays a role in CV events and he considers which questions remain to be answered before broad clinical application of this concept.

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

Inflammation expert opinions

Aug. 28, 2017
Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.

GRAND DEBATE: Inflammation and cardiovascular disease

ESC 2017 - Barcelona

ESC 2017 Grand Debate
ESC 2017 Grand Debate

ESC 2017 One of the Grand Debates of course focused on different interpretations of the CANTOS trial data. Paul Ridker and Alberico Catapano debated how central inflammation is to CVD.

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

Aug. 27, 2017
**ESC 2017** Peter Libby, who started basic research on the role of IL-1 in atherogenesis 30 years ago, gives his perspective on the CANTOS results, including the preliminary results that hint at a reduction in cancer fatalities.

ESC 2017 Peter Libby, who started basic research on the role of IL-1 in atherogenesis 30 years ago, gives his perspective on the CANTOS results, including the preliminary results that hint at a reduction in cancer fatalities.

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

ESC 2017 - Barcelona

Aug. 27, 2017
Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician, in which lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.

ESC 2017 Paul Ridker shares what the results of the CANTOS trial mean to him as a clinician. Lowering inflammation by inhibiting IL-1β with canakinumab reduced CV events in aggressively treated CV patients.

CANTOS results show that inhibiting inflammation reduces CV events and possibly lung cancer rates

ESC 2017 - Barcelona

Aug. 27, 2017 - news

ESC 2017 Inhibition of IL-1β with canakinumab significantly lowered hsCRP levels and CV events, especially in those with higher than median CRP reduction, and incident lung cancer and lung cancer mortality were reduced.

Anti-PCSK9-vaccination has anti-atherogenic effects in mice

June 26, 2017 - news

Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started

Investigational IL-1β-blocker targeting inflammation meets primary endpoint in outcome study

June 22, 2017
Phase III CANTOS study shows IL-1β-blocker ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis

The phase III CANTOS study shows ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis.

Frequency and duration of tooth brushing is associated with endothelial function

June 19, 2017 - Matsui S et al. - Int J Cardiol 2017
High frequency and long duration of tooth brushing were associated with a better endothelial function, implying that adequate tooth brushing may contribute to the prevention of CV events.

High frequency and long duration of tooth brushing were associated with a better endothelial function, implying that adequate tooth brushing may contribute to the prevention of CV events.

BET inhibitor downregulates components of complement cascade

June 6, 2017 - Wasiak S, et al. - JCTR 2017

In addition to improving the lipoprotein and inflammatory profile, in vitro and in vivo experiments, as well as protein profiling of patient samples showed RVX-208 modulates the complement cascade.

HIV as a model to study effect of chronic inflammation on CV risk

Mar. 16, 2017 - VBWG ACC 2017
HIV-infected persons have increased CV risk. Even when HIV is adequately suppressed, chronic inflammation persists. Studying this condition can give insights in how to reduce CV risk and possibly HIV infection in these individuals.

VBWG ACC 2017 HIV-infected persons have increased CV risk. Even when HIV is adequately suppressed, chronic inflammation persists. Studying this condition can give insights in how to reduce CV risk and possibly HIV infection in these individuals.

New fully human PCSK9 antibody successful in phase 2 trial

(from the Phase 2 EQUATOR Study)

Apr. 26, 2017 - Baruch A, et al. - Am J Cardiol. 2017
RG7652, a fully human PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events in coronary heart disease patients

RG7652, a PCSK9 antibody, dose-dependently reduced LDL-c, ApoB and Lp(a), but not inflammatory proteins, without concerning adverse events.